Journal of Pharmacogenomics & Pharmacoproteomics

Nagilla Oliveira

Publications

• Research Article
  Influence of SLCO1B1 and SLCO2B1 Polymorphisms on Tacrolimus Pharmacokinetics and Clinical Response
  Author(s): Camila Alves, Claudia R Felipe, Alvaro M Nishikawa, Patricia C Salgado, Cristina Fajardo, Helio T Silva Jr, Jose Osmar M Pestana, Denize Zetchaku, Glaucio Spinelli, Nagilla Oliveira, Mario Hiroyuki Hirata, Rosario DC Hirata and Alice C RodriguesCamila Alves, Claudia R Felipe, Alvaro M Nishikawa, Patricia C Salgado, Cristina Fajardo, Helio T Silva Jr, Jose Osmar M Pestana, Denize Zetchaku, Glaucio Spinelli, Nagilla Oliveira, Mario Hiroyuki Hirata, Rosario DC Hirata and Alice C Rodrigues
  
  Background: Immunosuppressant such as tacrolimus have narrow therapeutic range and are often associated with increased risk of nefrotoxicity in individuals that receive this drug after renal transplantation. Variants in transporters genes have been associated with variability in plasma concentration of tacrolimus and higher risk of adverse effects. Our aim was to investigate the effect of SLCO1B1 (c.388A>G, c.521T>C) and SLCO2B1 (c.- 71T>C) variants on the efficacy and safety of tacrolimus immunosuppressive therapy in kidney transplant recipients. Methods: SLCO1B1 and SLCO2B1 polymorphisms were detected by TaqMan genotyping and were associated to tacrolimus pharmacokinetics and incidence of acute rejection or diarrhea. Results: Carriers of the allele SLCO1B1 c.388G had lower dose adjusted blood concentration (.. View More»
  DOI: 10.4172/2153-0645.1000134

  Abstract PDF